Results presented at the American Orthopaedic Foot & Ankle Society Annual Meeting showed GLP-1 receptor agonists were not associated with increased fracture risk in patients with obesity or type 2 diabetes. "We did not see the signal that I and many other doctors are worried about, that GLP-1-related weight loss is associated with more fragility fractures," Christopher E.
Results presented at the American Orthopaedic Foot & Ankle Society Annual Meeting showed GLP-1 receptor agonists were not associated with increased fracture risk in patients with obesity or type 2 diabetes.
"We did not see the signal that I and many other doctors are worried about, that GLP-1-related weight loss is associated with more fragility fractures," Christopher E.
Gross, MD, FAAOS, FAOA, director of the foot and ankle division at the Medical University of South Carolina, told Healio.
The page is ready to read now. The fuller skim-friendly version will appear here automatically.
Results presented at the American Orthopaedic Foot & Ankle Society Annual Meeting showed GLP-1 receptor agonists were not associated with increased fracture risk in patients with obesity or type 2 diabetes. "We did not see the signal that I and many other doctors are worried about, that GLP-1-related weight loss is associated with more fragility fractures," Christopher E. Gross, MD, FAAOS, FAOA, director of the foot and ankle division at the Medical University of South Carolina, told Healio.
"In fact, we found the opposite association." In a cohort study, Gross and
Open the app view to save this story, compare related coverage, and continue from the same source.